JPMorgan analyst Jessica Fye says that in a positive surprise from the European Hematology Association website, initial CARTITUDE-4 details were unveiled with a progression-free survival hazard ratio "beating even the most lofty expectations." Carvykti’s progression-free survival hazard ratio came in at a "stunning" 0.26, the analyst tells investors in a research note. The firm believes these data strongly support the use of Carvykti in earlier lines of therapy and a "robust" peak sales opportunity. It keeps an Overweight rating on Legend Biotech.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LEGN:
- Legend Biotech Soars after Leaked Cancer Therapy Data
- Legend Biotech appoints Mythili Koneru, M.D. as CMO
- Legend Biotech establishes strategic advisory board
- Legend Biotech reports FY22 EPS ($1.40), consensus ($1.48)
- Legend Biotech initiated with a Buy at H.C. Wainwright
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue